Healthcare - Page 1 | TalkMarkets
All Posts > Content under Healthcare
1 to 16 of 4500 Posts
1 2 3 ... 282
Abbott (ABT) Beats Earnings And Sales In Q3, Tweaks View
Article By: Zacks Investment Research
Wednesday, October 18, 2017 10:57 AM EDT
Abbott Labs posted third quarter revenues of $6.82 billion surpassing the Zacks Consensus Estimate for revenues of $6.71 billion.
In this article: ABT
Amgen May Pull Back Before The Next Surge
Article By: Bob Lang
Wednesday, October 18, 2017 9:38 AM EDT
Will Amgen provide another ideal entry point? The chart says yes.
In this article: AMGN
Merck Upgraded To Buy From Neutral At Citi
Article By: The Fly
Wednesday, October 18, 2017 6:53 AM EDT
The analyst revised his initial PDx market estimates of $35bn to at least $50bn and increased his 2025 Keytruda forecasts from $9B to$15B.
In this article: MRK Also: LLY, RHHBY
Your Stake In The $22 Billion Dollar Cannabis Industry
Article By: Modest Money
Wednesday, October 18, 2017 4:54 AM EDT
Is now the right time to invest in the Cannabis Industry? The Cannabis Stock Index is up 26.4% month-to-date.
In this article: SMG, VRX, ABBV, INSY
Shire Plc (ADR) In The Spotlight As Activist Fund Sachem Pushes For More Divestment
Article By: Insider Monkey
Tuesday, October 17, 2017 5:17 PM EDT
Although M&A is a frequent occurrence in the biotech sector, major M&A is normally less common for large cap stocks.
In this article: SHPG Also: ADSK
UnitedHealth (UNH) Beats On Q3 Earnings, Guides Higher
Article By: Zacks Investment Research
Tuesday, October 17, 2017 8:29 AM EDT
UnitedHealth came out with earnings per share of $2.66, beating the Zacks Consensus Estimate of $2.57. Results were aided by higher revenues from both its segments – UnitedHealthcare and Optum.
In this article: UNH
Exelixis Surges After Cabometyx Granted Priority Review, Meets Endpoint In Trial
Article By: The Fly
Monday, October 16, 2017 12:50 PM EDT
Shares of Exelixis jumped in early trading after the biopharmaceutical company said it received priority review from the U.S. Food and Drug Administration for a treatment for advanced renal cell carcinoma.
In this article: EXEL Also: IPSEY, BAYRY
3 Market-Beating Stocks For Your 2018 Radar (With Extreme Upside Potential)
Article By: TipRanks
Monday, October 16, 2017 8:47 AM EDT
This little-known biotech stock has only received three buy ratings from top analysts in the last three months. However, these three analysts are all confident on one thing: that Gemphire has serious upside potential.
In this article: MCRB, LITE, GEMP
Week In Review: How Trump's Policies Moved Stocks - Sunday, Oct. 15
Article By: The Fly
Sunday, October 15, 2017 3:43 AM EDT
Insurers and hospital operators were under pressure on Friday after President Trump announced plans to cut off subsidy payments to insurers selling Affordable Care Act Coverage.
In this article: AET, CNC, HCA, HUM, JPM, NYT, GOOG, NWSA, FB, TWTR
How To Get Involved In The Drug Trade (It’s Not What You Think)
Article By: David Zarling
Saturday, October 14, 2017 11:58 AM EDT
Eli Lilly & Co. (LLY), one of the world’s largest drug manufacturers, has seen its stock go nowhere for 2 years. This after Lilly was up over 350% from the bottom in 2009 through September 2015. Last week, it broke out of the 2-year base.
In this article: LLY
Inotek Jumps After Detailing Rocket's Near-Term Clinical Catalysts
Article By: The Fly
Friday, October 13, 2017 3:12 PM EDT
Inotek Pharmaceuticals last night announced the filing with the SEC of the company's preliminary proxy statement in connection with the previously announced proposed combination with Rocket Pharmaceuticals.
In this article: ITEK
Teva Maneuvers To Match 30% Discounts For Generic Copaxone
Article By: Shock Exchange
Friday, October 13, 2017 12:09 PM EDT
Market chatter suggests Mylan is offering 25%-30% discounts on generic Copaxone, and Teva is scrambling to match the discounts. If Teva has to lower Q4 earnings guidance investors could punish the stock.
In this article: TEVA, MYL
Allergan Says Mohawks Bought Restasis Patents With Immunity Promise
Article By: Shock Exchange
Friday, October 13, 2017 10:36 AM EDT
AGN the Mohawks brought Restasis patents with a promise of immunity. I estimate the patents are worth $14B. The patent judge want to determine if the deal was a sham.
In this article: AGN Also: MYL, TEVA
Hot Options Report For End Of Day - Thursday, October 12
Article By: The Options Insider
Thursday, October 12, 2017 6:02 PM EDT
The most active equity options and strikes for end of the day: GE, T, AMAT, CMCSA, BAC, ESRX and AAPL.
In this article: GE, T, AMAT, CMCSA, BAC, AAPL, ESRX
Wells Fargo Says Buy Micro-Cap Drugmaker Ahead Of Cancer Immunotherapy Meeting
Article By: The Fly
Thursday, October 12, 2017 12:31 PM EDT
Shares of Infinity Pharmaceuticals are on the rise after Wells Fargo analyst Jim Birchenough upgraded the stock to a buy-equivalent rating.
In this article: INFI Also: FPRX
5 Pharma & Biotech Stocks That Could Be Big Winners In Q3 Earnings
Article By: Arpita Dutt
Tuesday, October 10, 2017 4:34 PM EDT
Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses. So far this year, the Nasdaq Biotechnology Index is up 25.6%.
In this article: LLY, MRK, PFE, BIIB, VRTX Also: NVS, GILD
1 to 16 of 4500 Posts
1 2 3 ... 282